Immunic (NASDAQ:IMUX) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Immunic (NASDAQ:IMUX) from a hold rating to a sell rating in a research report sent to investors on Saturday,Wall Street Zen reports.

A number of other equities research analysts also recently weighed in on the stock. LADENBURG THALM/SH SH raised shares of Immunic to a “strong-buy” rating in a research note on Wednesday, July 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Immunic in a report on Wednesday, August 26th. Wedbush reaffirmed an “outperform” rating and issued a $45.00 price objective on shares of Immunic in a research note on Thursday, September 10th. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Immunic in a research note on Thursday, September 10th. Finally, Roth Capital reaffirmed a “buy” rating on shares of Immunic in a report on Tuesday, September 1st. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $35.43.

Immunic Stock Performance

Shares of NASDAQ IMUX opened at $7.95 on Friday. Immunic has a 52-week low of $5.06 and a 52-week high of $17.43. The business has a fifty day moving average of $12.48 and a two-hundred day moving average of $12.77. The stock has a market cap of $108.44 million, a PE ratio of -1.82 and a beta of 1.45.

Immunic (NASDAQ:IMUX) last announced its earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.36. Analysts predict that Immunic will post -3.71 earnings per share for the current year.

Institutional Investors Weigh In On Immunic

Institutional investors have recently added to or reduced their stakes in the stock. CTC Alternative Strategies Ltd. bought a new stake in Immunic in the 1st quarter valued at $27,000. ADAR1 Capital Management LLC acquired a new position in Immunic in the 1st quarter valued at $33,000. Seven Fleet Capital Management LP acquired a new position in Immunic in the 4th quarter valued at $83,000. Bank of America Corp DE grew its holdings in Immunic by 80,724.2% in the 1st quarter. Bank of America Corp DE now owns 143,867 shares of the company’s stock valued at $160,000 after buying an additional 143,689 shares in the last quarter. Finally, Connective Capital Management LLC bought a new position in Immunic during the 4th quarter worth $161,000. 51.82% of the stock is owned by institutional investors.

About Immunic

Immunic, Inc is a clinical-stage biotechnology company developing orally administered therapies for chronic inflammatory and autoimmune diseases. The company focuses on selectively modulating the immune system while seeking to avoid broad immunosuppression, with an emphasis on conditions affecting the central nervous system and gastrointestinal tract.

Immunic’s lead investigational product is vidofludimus calcium, formerly known as IMU-838. The oral, selective dihydroorotate dehydrogenase inhibitor is being studied in clinical trials for multiple sclerosis, including relapsing and progressive forms of the disease.